You are here:

paclitaxel albumin (Abraxane)

Advice

following a resubmission considered under the end of life / orphan medicine process:

paclitaxel albumin (Abraxane®) is accepted for use within NHS Scotland.

Indication under review: in combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

In a randomised, phase III, open-label study paclitaxel albumin plus gemcitabine treatment improved median overall survival by 1.8 months compared with gemcitabine alone.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: paclitaxel albumin (Abraxane)
SMC Drug ID: 968/14
Manufacturer: Celgene Ltd
Indication: In combination with gemcitabine for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Resubmission
Status: Accepted
Date Advice Published: 9 February 2015

Archived Advice

Full submission 9 June 2014

Back